Trial · NCT05052983
Results by group26
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 26
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Time From Baseline to Relapse Meeting At Least 1 of the Defined Criteria | Nemolizumab | NA | 95% Confidence Interval NA to NA | Days | |
| Time From Baseline to Relapse Meeting At Least 1 of the Defined Criteria | Placebo | 112.50 | 95% Confidence Interval 84.00 to 161.00 | Days | |
| Percentage of Participants Maintaining Investigator Global Assessment (IGA) Success at Each Scheduled Visit | Nemolizumab | At Week 4 | 88.2 | Percentage of Participants | |
| Percentage of Participants Maintaining Investigator Global Assessment (IGA) Success at Each Scheduled Visit | Placebo | At Week 4 | 86.7 | Percentage of Participants | |
| Percentage of Participants Maintaining Investigator Global Assessment (IGA) Success at Each Scheduled Visit | Nemolizumab | At Week 8 | 82.4 | Percentage of Participants | |
| Percentage of Participants Maintaining Investigator Global Assessment (IGA) Success at Each Scheduled Visit | Placebo | At Week 8 | 81.3 | Percentage of Participants | |
| Percentage of Participants Maintaining Investigator Global Assessment (IGA) Success at Each Scheduled Visit | Nemolizumab | At Week 12 | 88.2 | Percentage of Participants | |
| Percentage of Participants Maintaining Investigator Global Assessment (IGA) Success at Each Scheduled Visit | Placebo | At Week 12 | 53.3 | Percentage of Participants | |
| Percentage of Participants Maintaining Investigator Global Assessment (IGA) Success at Each Scheduled Visit | Nemolizumab | At Week 16 | 81.3 | Percentage of Participants | |
| Percentage of Participants Maintaining Investigator Global Assessment (IGA) Success at Each Scheduled Visit | Placebo | At Week 16 | 27.3 | Percentage of Participants | |
| Percentage of Participants Maintaining Investigator Global Assessment (IGA) Success at Each Scheduled Visit | Nemolizumab | At Week 20 | 86.7 | Percentage of Participants | |
| Percentage of Participants Maintaining Investigator Global Assessment (IGA) Success at Each Scheduled Visit | Placebo | At Week 20 | 57.1 | Percentage of Participants | |
| Percentage of Participants Maintaining Investigator Global Assessment (IGA) Success at Each Scheduled Visit | Nemolizumab | At Week 24 | 85.7 | Percentage of Participants | |
| Percentage of Participants Maintaining Investigator Global Assessment (IGA) Success at Each Scheduled Visit | Placebo | At Week 24 | 60.0 | Percentage of Participants | |
| Percentage of Participants With Increase in Peak Pruritus (PP) Numeric Rating Scale (NRS) Score of >= 4 Points From Baseline at Each Scheduled Visit | Nemolizumab | At Week 4 | 0 | Percentage of Participants | |
| Percentage of Participants With Increase in Peak Pruritus (PP) Numeric Rating Scale (NRS) Score of >= 4 Points From Baseline at Each Scheduled Visit | Placebo | At Week 4 | 0 | Percentage of Participants | |
| Percentage of Participants With Increase in Peak Pruritus (PP) Numeric Rating Scale (NRS) Score of >= 4 Points From Baseline at Each Scheduled Visit | Nemolizumab | At Week 8 | 0 | Percentage of Participants | |
| Percentage of Participants With Increase in Peak Pruritus (PP) Numeric Rating Scale (NRS) Score of >= 4 Points From Baseline at Each Scheduled Visit | Placebo | At Week 8 | 0 | Percentage of Participants | |
| Percentage of Participants With Increase in Peak Pruritus (PP) Numeric Rating Scale (NRS) Score of >= 4 Points From Baseline at Each Scheduled Visit | Nemolizumab | At Week 12 | 0 | Percentage of Participants | |
| Percentage of Participants With Increase in Peak Pruritus (PP) Numeric Rating Scale (NRS) Score of >= 4 Points From Baseline at Each Scheduled Visit | Placebo | At Week 12 | 16.7 | Percentage of Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05052983/results